Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Tofacitinib in the treatment of active rheumatoid arthritis - single-centre experience.

Madej M, Woytala P, Frankowski M, Lubiński Ł, Sokolik R, Sebastian A, Maciążek-Chyra B, Wiland P.

Reumatologia. 2019;57(4):192-198. doi: 10.5114/reum.2019.87609. Epub 2019 Aug 31.

2.

Factors associated with quality of life in systemic sclerosis: a cross-sectional study.

Sierakowska M, Doroszkiewicz H, Sierakowska J, Olesińska M, Grabowska-Jodkowska A, Brzosko M, Leszczyński P, Pawlak-Buś K, Batko B, Wiland P, Majdan M, Bykowska-Sochacka M, Romanowski W, Zon-Giebel A, Jeka S, Ndosi M.

Qual Life Res. 2019 Dec;28(12):3347-3354. doi: 10.1007/s11136-019-02284-9. Epub 2019 Sep 3.

3.

Panta rhei in diagnosing rheumatic diseases.

Wiland P.

Reumatologia. 2019;57(3):127-128. doi: 10.5114/reum.2019.86421. Epub 2019 Jun 28. No abstract available.

4.

Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial.

Shim SC, Božić-Majstorović L, Berrocal Kasay A, El-Khouri EC, Irazoque-Palazuelos F, Cons Molina FF, Medina-Rodriguez FG, Miranda P, Shesternya P, Chavez-Corrales J, Wiland P, Jeka S, Garmish O, Hrycaj P, Fomina N, Park W, Suh CH, Lee SJ, Lee SY, Bae YJ, Yoo DH.

Rheumatology (Oxford). 2019 Dec 1;58(12):2193-2202. doi: 10.1093/rheumatology/kez152.

5.

Comorbidity burden and clinical characteristics of patients with difficult-to-control rheumatoid arthritis.

Batko B, Urbański K, Świerkot J, Wiland P, Raciborski F, Jędrzejewski M, Koziej M, Cześnikiewicz-Guzik M, Guzik TJ, Stajszczyk M.

Clin Rheumatol. 2019 Sep;38(9):2473-2481. doi: 10.1007/s10067-019-04579-1. Epub 2019 May 10.

PMID:
31076943
6.

The effect of LILRB1 but not LILRA3 gene polymorphism in immunopathology of ankylosing spondylitis-A parallel to KIR genes.

Majorczyk E, Wiśniewski A, Zoń-Giebel A, Chlebicki A, Wiland P, Kuśnierczyk P.

Int J Immunogenet. 2019 Jun;46(3):146-151. doi: 10.1111/iji.12422. Epub 2019 Mar 20.

PMID:
30892832
7.

Relapsing polychondritis - analysis of symptoms and criteria.

Maciążek-Chyra B, Szmyrka M, Skoczyńska M, Sokolik R, Lasocka J, Wiland P.

Reumatologia. 2019;57(1):8-18. doi: 10.5114/reum.2019.83234. Epub 2019 Feb 28.

8.

Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial.

Suh CH, Yoo DH, Berrocal Kasay A, Chalouhi El-Khouri E, Cons Molina FF, Shesternya P, Miranda P, Medina-Rodriguez FG, Wiland P, Jeka S, Chavez-Corrales J, Linde T, Hrycaj P, Abello-Banfi M, Hospodarskyy I, Jaworski J, Piotrowski M, Brzosko M, Krogulec M, Shevchuk S, Calvo A, Andersone D, Park W, Shim SC, Lee SJ, Lee SY.

BioDrugs. 2019 Feb;33(1):79-91. doi: 10.1007/s40259-018-00331-4.

9.

Prevalence and clinical characteristics of rheumatoid arthritis in Poland: a nationwide study.

Batko B, Stajszczyk M, Świerkot J, Urbański K, Raciborski F, Jędrzejewski M, Wiland P.

Arch Med Sci. 2019 Jan;15(1):134-140. doi: 10.5114/aoms.2017.71371. Epub 2017 Dec 13.

10.

Immunohistochemical and ultrastructural analysis of sporadic inclusion body myositis: a case series.

Haczkiewicz K, Sebastian A, Piotrowska A, Misterska-Skóra M, Hałoń A, Skoczyńska M, Sebastian M, Wiland P, Dzięgiel P, Podhorska-Okołów M.

Rheumatol Int. 2019 Jul;39(7):1291-1301. doi: 10.1007/s00296-018-4221-z. Epub 2018 Dec 8.

PMID:
30535925
11.

Autoantibody and metalloproteinase activity in early arthritis.

Ponikowska M, Świerkot J, Nowak B, Korman L, Wiland P.

Clin Rheumatol. 2019 Mar;38(3):827-834. doi: 10.1007/s10067-018-4326-5. Epub 2018 Nov 7.

PMID:
30406565
12.

Dysregulated interferon-γ and interleukin-2 synthesis in peripheral blood T cells in quiescent systemic lupus erythematosus is dependent on the affected T-cell receptor ζ chain expression.

Szmyrka M, Ciszak L, Węglarz M, Andrzejewska K, Wiland P, Kosmaczewska A.

Pol Arch Intern Med. 2018 Oct 31;128(10):626-630. doi: 10.20452/pamw.4337. Epub 2018 Sep 21. No abstract available.

13.

Interstitial lung disease in systemic sclerosis: challenges in early diagnosis and management.

Chowaniec M, Skoczyńska M, Sokolik R, Wiland P.

Reumatologia. 2018;56(4):249-254. doi: 10.5114/reum.2018.77977. Epub 2018 Aug 31. Review.

14.

Biosimilar switching - current state of knowledge.

Wiland P, Batko B, Brzosko M, Kucharz EJ, Samborski W, Świerkot J, Więsik-Szewczyk E, Feldman J.

Reumatologia. 2018;56(4):234-242. doi: 10.5114/reum.2018.77975. Epub 2018 Aug 31. Review.

15.

Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology.

Kucharz EJ, Stajszczyk M, Kotulska-Kucharz A, Batko B, Brzosko M, Jeka S, Leszczyński P, Majdan M, Olesińska M, Samborski W, Wiland P.

Reumatologia. 2018;56(4):203-211. doi: 10.5114/reum.2018.77971. Epub 2018 Aug 31.

16.

Systemic Lupus Erythematosus Induced by Autoimmune/ Inflammatory Syndrome Induced by Adjuvants. Is it Possible? Long-Term Follow-up and Literature Review.

Sebastian A, Butrym A, Misterska Skóra M, Chlebicki A, Mazur G, Wiland P.

Arch Rheumatol. 2018 Jan 15;33(2):247-249. doi: 10.5606/ArchRheumatol.2018.6730. eCollection 2018 Jun. No abstract available.

17.

How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project).

Brito-Zerón P, Acar-Denizli N, Ng WF, Zeher M, Rasmussen A, Mandl T, Seror R, Li X, Baldini C, Gottenberg JE, Danda D, Quartuccio L, Priori R, Hernandez-Molina G, Armagan B, Kruize AA, Kwok SK, Kvarnström M, Praprotnik S, Sène D, Bartoloni E, Solans R, Rischmueller M, Suzuki Y, Isenberg DA, Valim V, Wiland P, Nordmark G, Fraile G, Bootsma H, Nakamura T, Giacomelli R, Devauchelle-Pensec V, Knopf A, Bombardieri M, Trevisani VF, Hammenfors D, Pasoto SG, Retamozo S, Gheita TA, Atzeni F, Morel J, Vollenveider C, Horvath IF, Sivils KL, Olsson P, De Vita S, Sánchez-Guerrero J, Kilic L, Wahren-Herlenius M, Mariette X, Ramos-Casals M; Sjögren Big Data Consortium.

Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):102-112. Epub 2018 Aug 14.

18.

Satisfaction and discontent of Polish patients with biological therapy of rheumatic diseases: results of a multi-center questionnaire study.

Kotulska A, Kucharz EJ, Wiland P, Olesińska M, Felis-Giemza A, Kopeć-Mędrek M, Zoń-Giebel A, Romanowski W, Szymczak-Bartz L, Tłustochowicz M, Lewandowicz J, Kowalska-Majka J, Bucka J, Majdan M, Kiełbik Z, Korkosz M, Bielińska A, Leszczyński P, Pawlak-Buś K, Puszczewicz MJ, Majewski D, Smolik K, Migas-Kukla T, Sochocka-Bykowska M, Szarecka M, Luberda B, Falenta-Hitnarowicz M, Świkszcz-Gniadek J, Lepiarz-Rusek W, Rozwadowski G, Chara B, Zajdel J, Zdrojewski Z, Maciejowska-Roge M, Rosmus-Kuczia I.

Reumatologia. 2018;56(3):140-148. doi: 10.5114/reum.2018.76901. Epub 2018 Jun 30.

19.

Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial.

Park W, Božić-Majstorović L, Milakovic D, Berrocal Kasay A, El-Khouri EC, Irazoque-Palazuelos F, Molina FFC, Shesternya P, Miranda P, Medina-Rodriguez FG, Wiland P, Jeka S, Chavez-Corrales J, Garmish O, Linde T, Rekalov D, Hrycaj P, Krause A, Fomina N, Piura O, Abello-Banfi M, Suh CH, Shim SC, Lee SJ, Lee SY, Kim SH, Yoo DH.

MAbs. 2018 Aug/Sep;10(6):934-943. doi: 10.1080/19420862.2018.1487912. Epub 2018 Jul 16.

20.

Cognitive impairment, event-related potentials and immunological status in patients with systemic lupus erythematosus.

Szmyrka M, Pokryszko-Dragan A, Słotwiński K, Gruszka E, Korman L, Podemski R, Wiland P.

Adv Clin Exp Med. 2019 Feb;28(2):185-192. doi: 10.17219/acem/76711.

21.

How to Distinguish Patients with pSS among Individuals with Dryness without Invasive Diagnostic Studies.

Sebastian A, Sebastian M, Misterska-Skóra M, Woytala P, Jakuszko K, Wiland P.

J Immunol Res. 2018 May 2;2018:1060421. doi: 10.1155/2018/1060421. eCollection 2018.

22.

Parameters of Somatosensory Evoked Potentials in Patients with Primary Sjӧgren's Syndrome: Preliminary Results.

Dziadkowiak E, Sebastian A, Wieczorek M, Kusińska E, Waliszewska-Prosół M, Wiland P, Ejma M.

J Immunol Res. 2018 Apr 5;2018:8174340. doi: 10.1155/2018/8174340. eCollection 2018.

23.

Septic arthritis of the sacroiliac joint.

Woytala PJ, Sebastian A, Błach K, Silicki J, Wiland P.

Reumatologia. 2018;56(1):55-58. doi: 10.5114/reum.2018.74752. Epub 2018 Feb 28.

24.

Methotrexate treatment for rheumatoid arthritis in Poland: Retrospective analysis of patients in routine clinical practice.

Świerkot J, Batko B, Wiland P, Jędrzejewski M, Stajszczyk M.

Reumatologia. 2018;56(1):3-9. doi: 10.5114/reum.2018.74741. Epub 2018 Feb 28.

25.

Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis.

Iwaszko M, Świerkot J, Kolossa K, Jeka S, Wiland P, Bogunia-Kubik K.

Genes (Basel). 2018 Jan 25;9(2). pii: E64. doi: 10.3390/genes9020064.

26.

Chest HRCT findings in patients with primary Sjögren's syndrome.

Sebastian A, Misterska-Skóra M, Silicki J, Sebastian M, Wiland P.

Adv Clin Exp Med. 2017 Oct;26(7):1101-1106. doi: 10.17219/acem/68978.

27.

Disease activity in axial spondyloarthritis after discontinuation of TNF inhibitors therapy.

Sebastian A, Wojtala P, Lubiński Ł, Mimier M, Chlebicki A, Wiland P.

Reumatologia. 2017;55(4):157-162. doi: 10.5114/reum.2017.69775. Epub 2017 Aug 31.

28.

The variety of clinical presentations in IgG4-related disease in Rheumatology.

Sebastian A, Sebastian M, Misterska-Skóra M, Donizy P, Hałoń A, Chlebicki A, Lipiński A, Wiland P.

Rheumatol Int. 2018 Feb;38(2):303-309. doi: 10.1007/s00296-017-3807-1. Epub 2017 Aug 30.

29.

Polymorphisms within Genes Involved in Regulation of the NF-κB Pathway in Patients with Rheumatoid Arthritis.

Gębura K, Świerkot J, Wysoczańska B, Korman L, Nowak B, Wiland P, Bogunia-Kubik K.

Int J Mol Sci. 2017 Jul 4;18(7). pii: E1432. doi: 10.3390/ijms18071432.

30.

The role of microRNA-5196 in the pathogenesis of systemic sclerosis.

Ciechomska M, Zarecki P, Merdas M, Swierkot J, Morgiel E, Wiland P, Maslinski W, Bogunia-Kubik K.

Eur J Clin Invest. 2017 Aug;47(8):555-564. doi: 10.1111/eci.12776. Epub 2017 Jul 18.

31.

Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial.

Yoo DH, Suh CH, Shim SC, Jeka S, Molina FFC, Hrycaj P, Wiland P, Lee EY, Medina-Rodriguez FG, Shesternya P, Radominski S, Stanislav M, Kovalenko V, Sheen DH, Myasoutova L, Lim MJ, Choe JY, Lee SJ, Lee SY, Kim SH, Park W.

BioDrugs. 2017 Aug;31(4):357-367. doi: 10.1007/s40259-017-0232-7.

32.

Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis.

Park W, Suh CH, Shim SC, Molina FFC, Jeka S, Medina-Rodriguez FG, Hrycaj P, Wiland P, Lee EY, Shesternya P, Kovalenko V, Myasoutova L, Stanislav M, Radominski S, Lim MJ, Choe JY, Lee SJ, Lee SY, Kim SH, Yoo DH.

BioDrugs. 2017 Aug;31(4):369-377. doi: 10.1007/s40259-017-0233-6.

33.

Results from Polish Spondyloarthritis Initiative registry (PolSPI) - methodology and data from - the first year of observation.

Guła Z, Barczyńska T, Brzosko M, Gąsowski J, Jeka S, Jodłowska-Cicio K, Kwaśny-Krochin B, Leszczyński P, Lubiński Ł, Łosińska K, Pawlak-Buś K, Przepiera-Będzak H, Samborski W, Schlabs M, Siedlar M, Sikorska D, Świerkot J, Węgierska M, Wiland P, Korkosz M.

Reumatologia. 2017;55(2):59-64. doi: 10.5114/reum.2017.67599. Epub 2017 Apr 28.

34.

Palpable mass of the neck in the course of Takayasu arteritis.

Andrzejewska K, Starba A, Misterska-Skóra M, Wiland P, Guziński M.

Reumatologia. 2017;55(1):48-52. doi: 10.5114/reum.2017.66688. Epub 2017 Mar 22.

35.

Antibodies against monomeric C-reactive protein - a promising biomarker of lupus nephritis?

Jakuszko K, Krajewska M, Kościelska-Kasprzak K, Myszka M, Sebastian A, Gniewek K, Wiland P, Klinger M.

Clin Biochem. 2017 Sep;50(13-14):756-762. doi: 10.1016/j.clinbiochem.2017.03.010. Epub 2017 Mar 12.

PMID:
28300543
36.

Dr. Wiland, et al, reply.

Wiland P, Dudler J, Veale D, Tahir H, Pedersen R, Bukowski J, Vlahos B, Williams T, Gaylord S, Kotak S.

J Rheumatol. 2017 Feb;44(2):259. doi: 10.3899/jrheum.161405. No abstract available.

PMID:
28148758
37.

EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis.

van Steenbergen HW, Aletaha D, Beaart-van de Voorde LJ, Brouwer E, Codreanu C, Combe B, Fonseca JE, Hetland ML, Humby F, Kvien TK, Niedermann K, Nuño L, Oliver S, Rantapää-Dahlqvist S, Raza K, van Schaardenburg D, Schett G, De Smet L, Szücs G, Vencovský J, Wiland P, de Wit M, Landewé RL, van der Helm-van Mil AH.

Ann Rheum Dis. 2017 Mar;76(3):491-496. doi: 10.1136/annrheumdis-2016-209846. Epub 2016 Oct 6.

PMID:
27991858
38.

The Activity of JAK/STAT and NF-κB in Patients with Rheumatoid Arthritis.

Świerkot J, Nowak B, Czarny A, Zaczyńska E, Sokolik R, Madej M, Korman L, Sebastian A, Wojtala P, Lubiński Ł, Wiland P.

Adv Clin Exp Med. 2016 Jul-Aug;25(4):709-17. doi: 10.17219/acem/61034.

39.

The Safety of Intravenous Cyclophosphamide in the Treatment of Rheumatic Diseases.

Woytala PJ, Morgiel E, Łuczak A, Czesak-Woytala K, Wiland P.

Adv Clin Exp Med. 2016 May-Jun;25(3):479-84. doi: 10.17219/acem/28736.

40.

A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis.

Yoo DH, Suh CH, Shim SC, Jeka S, Cons-Molina FF, Hrycaj P, Wiland P, Lee EY, Medina-Rodriguez FG, Shesternya P, Radominski S, Stanislav M, Kovalenko V, Sheen DH, Myasoutova L, Lim MJ, Choe JY, Lee SJ, Lee SY, Kwon TS, Park W.

Ann Rheum Dis. 2017 Mar;76(3):566-570. doi: 10.1136/annrheumdis-2016-209540. Epub 2016 Sep 13.

41.

Erythema nodosum - presentation of three cases.

Starba A, Chowaniec M, Wiland P.

Reumatologia. 2016;54(2):83-5. doi: 10.5114/reum.2016.60218. Epub 2016 Jun 3.

42.

Erythema nodosum - review of the literature.

Chowaniec M, Starba A, Wiland P.

Reumatologia. 2016;54(2):79-82. doi: 10.5114/reum.2016.60217. Epub 2016 Jun 3. Review.

43.

The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis.

Wiland P, Dudler J, Veale D, Tahir H, Pedersen R, Bukowski J, Vlahos B, Williams T, Gaylord S, Kotak S.

J Rheumatol. 2016 Jul;43(7):1268-77. doi: 10.3899/jrheum.151179. Epub 2016 Jun 1.

PMID:
27252426
44.

Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.

Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, Baranauskaite A, Wiland P, Abud-Mendoza C, Oparanov B, Smiyan S, Kim H, Lee SJ, Kim S, Park W.

Ann Rheum Dis. 2017 Feb;76(2):355-363. doi: 10.1136/annrheumdis-2015-208786. Epub 2016 Apr 29.

45.

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.

Park W, Yoo DH, Miranda P, Brzosko M, Wiland P, Gutierrez-Ureña S, Mikazane H, Lee YA, Smiyan S, Lim MJ, Kadinov V, Abud-Mendoza C, Kim H, Lee SJ, Bae Y, Kim S, Braun J.

Ann Rheum Dis. 2017 Feb;76(2):346-354. doi: 10.1136/annrheumdis-2015-208783. Epub 2016 Apr 26.

46.

[Immunological markers of rheumatoid arthritis].

Matuszewska A, Madej M, Wiland P.

Postepy Hig Med Dosw (Online). 2016 Mar 25;70:251-7. doi: 10.5604/17322693.1198270. Review. Polish.

47.

Disease Activity, Oxidized-LDL Fraction and Anti-Oxidized LDL Antibodies Influence Cardiovascular Risk in Rheumatoid Arthritis.

Nowak B, Madej M, Łuczak A, Małecki R, Wiland P.

Adv Clin Exp Med. 2016 Jan-Feb;25(1):43-50. doi: 10.17219/acem/29847.

48.

Activity of JAK/STAT and NF-kB in patients with axial spondyloarthritis.

Świerkot J, Sokolik R, Czarny A, Zaczyńska E, Nowak B, Chlebicki A, Korman L, Madej M, Wojtala P, Lubiński Ł, Wiland P.

Postepy Hig Med Dosw (Online). 2015 Dec 2;69:1291-8.

49.

Reported concepts for the treatment modalities and pain management of temporomandibular disorders.

Wieckiewicz M, Boening K, Wiland P, Shiau YY, Paradowska-Stolarz A.

J Headache Pain. 2015;16:106. doi: 10.1186/s10194-015-0586-5. Epub 2015 Dec 7. Review.

50.

Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment.

Iwaszko M, Świerkot J, Kolossa K, Jeka S, Wiland P, Bogunia-Kubik K.

Joint Bone Spine. 2016 Jan;83(1):75-9. doi: 10.1016/j.jbspin.2015.06.010. Epub 2015 Oct 6.

PMID:
26453102

Supplemental Content

Loading ...
Support Center